Cypress Bioscience introduces two new personalized medicine services

According to the company, the initial personalized medicine services facilitate improved diagnostic, prognostic and therapeutic decision making for rheumatologists treating patients with rheumatoid arthritis (RA).

Avise PG is a test that supports dose optimization and therapeutic decision making for patients taking methotrexate (MTX), a first-line therapy for RA. Avise PG offers rheumatologists insight into a patient’s metabolism of MTX by measuring levels of MTX polyglutamates, the active metabolites of MTX, the company said.

Avise MCV is a sensitive and specific test that improves upon traditional biomarkers used to help diagnose RA. Avise MCV is used for first-line diagnostic testing of patients who present with symptoms of RA, and offers prognostic insight with respect to disease progression while improving diagnostic accuracy, said Cypress.

Jay Kranzler, chairman and CEO of Cypress Bioscience, said: “The launch of these personalized medicine services represents an important milestone in our maturation to a uniquely positioned commercial enterprise.

“Cypress Bioscience now has a product candidate, milnacipran, currently under NDA review at the FDA as a therapy for the management of fibromyalgia, and a sales force that will be detailing our personalized medicine services to rheumatologists. This strategic approach reflects our ongoing commitment to partnering with these specialists.”